Drugs & Aging

, Volume 15, Issue 3, pp 183–195 | Cite as

Raynaud’s Phenomenon in Older Adults

Diagnostic Considerations and Management
  • Shari M. Ling
  • Fredrick M. Wigley
Disease Management

Abstract

Raynaud’s phenomenon (RP) is characterised by sensitivity to cold temperatures associated with either biphasic or uniphasic change in colour of the digits. Since few studies are available which include older adults, the prevalence of RP in the older adult population is estimated from surveys or studies of the general population. The causes of RP in older adults may differ significantly from those in young adults and, therefore, so would the evaluation of RP. Because of comorbities that accompany advancing age, the managment of RP in older adult patients must take into consideration toxicity and adverse reactions that may develop, especially in the frail individual. Although nonpharmacological therapy is preferable, slow-release calcium antagonists provide a relatively well tolerated and effective treatment for moderate to severe RP in older adult patients. Aggressive treatment including hospitalisation is appropriate for older adult patients during periods of critical digital ischaemia associated with RP.

Keywords

Adis International Limited Calcium Antagonist Scleroderma Nicardipine Iloprost 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Belch JJ, Kahn F. Primary Raynaud’s is a disease or disorder: it is not merely a trait. J Rheumatol 1998; 25: 2295–7PubMedGoogle Scholar
  2. 2.
    Hadler NM. ‘Primary Raynaud’s’ is not a disease or even a disorder; it’s a trait. J Rheumatol 1998; 25: 2291–4PubMedGoogle Scholar
  3. 3.
    LeRoy EC, Medsger TA. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10: 485–8PubMedGoogle Scholar
  4. 4.
    Brennan P, Silman A, Black C, et al. Validity and reliability of three methods used in the diagnosis of Raynaud’s phenomenon: the UK Scleroderma Study Group. Br JRheumatol 1993; 32: 357–61CrossRefGoogle Scholar
  5. 5.
    Wigley FM, Flavahan NA. Raynaud’s phemonenon. Rheum Dis Clin North Am 1996; 22: 765–81PubMedCrossRefGoogle Scholar
  6. 6.
    Maricq H, Weinrich MC. Diagnosis of Raynaud’s phenomenon assisted by color charts. J Rheumatol 1988; 15: 4554–9Google Scholar
  7. 7.
    Gelber A, Wigley F, Stallings R, et al. Raynaud’s phenomenon in a poor, urban, African-American community. Arthritis Rheum 1996; 39 Suppl.: S149Google Scholar
  8. 8.
    Planchon B, Pistorius A, Beurrier P, et al. Primary Raynaud’s phenomenon: age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994; 45: 677–86PubMedCrossRefGoogle Scholar
  9. 9.
    Fraenkel L, Zyhang YQ, Evans S, et al. The association of estrogen replacement therapy and Raynaud’s phenomena in postmenopausal women. Ann Intern Med 1998; 129: 208–11PubMedGoogle Scholar
  10. 10.
    Sanchez-Guerrero J, Liang MH, Karlson CW, et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995; 122: 430–2PubMedGoogle Scholar
  11. 11.
    Seibold JR. Scleroderma. In: Kelley WN, Harris ED, Ruddy S, et al., editors. Textbook of rheumatology. 5th ed. Philadelphia: WB Saunders, 1997: 1133–2Google Scholar
  12. 12.
    Friedman EI, Taylor LM, Porter JM. Late-onset Raynaud’s syndrome: diagnostic and therapeutic considerations. Geriatrics 1988; 43: 59–69PubMedGoogle Scholar
  13. 13.
    Ling SM, Flynn J, Wigley F. Musculoskeletal diseases. In: Gallo JJ, Busby-Whitehead J, Rabins PV, et al., editors. Reichel’s care of the elderly: clinical aspects of aging. 5th ed. Baltimore (MD): William & Wilkins, 1999Google Scholar
  14. 14.
    Kellenberg CGM. Overlapping syndromes, undifferentiated connective tissue disease and other fibrosing conditions. Curr Opin Rheumatol 1995; 7: 568–73CrossRefGoogle Scholar
  15. 15.
    Baker SB. Late onset systemic lupus erythematosus. Am J Med 1979; 66: 727–32PubMedCrossRefGoogle Scholar
  16. 16.
    Baer AN, Pincus T. Occult systemic lupus erythematosus in elderly men. JAMA 1983; 249: 3350–2PubMedCrossRefGoogle Scholar
  17. 17.
    Nesher G, Moore TL, Suckner J. Rheumatoid arthritis in the elderly. J Am Geriatr Soc 1991; 39: 284–94PubMedGoogle Scholar
  18. 18.
    Grassi W, Blasetti P, Core P, et al. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol 1994; 33: 139–41PubMedCrossRefGoogle Scholar
  19. 19.
    Leppert J, Aberg H, Ringqvist I, et al. Raynaud’s phenomenon in a female population: prevalence and association with other conditions. Angiology 1987; 38: 871–7PubMedCrossRefGoogle Scholar
  20. 20.
    Inaba R, Maeda M, Fujita S, et al. Prevalence of Raynaud’s phenomenon and specific clinical signs related to progressive systemic sclerosis in the general population of Japan. Int J Dermatol 1993; 32: 652–5PubMedCrossRefGoogle Scholar
  21. 21.
    Allen EV, Brown GE. Raynaud’s disease: a clinical study of 147 cases. JAMA 1932; 183–200Google Scholar
  22. 22.
    Hines EA, Christensen NA. Raynaud’s disease among men. JAMA 1945; 129: 1–4CrossRefGoogle Scholar
  23. 23.
    Blain A, Coller FA, Carver GB, et al. Raynaud’s disease: a study of criteria for prognosis. Surgery 1951; 29: 387–97PubMedGoogle Scholar
  24. 24.
    Gifford RW, Hines EA. Raynaud’s disease among women and girls. Circulation 1957; 16: 1012PubMedCrossRefGoogle Scholar
  25. 25.
    Nielubowicz J, Zajac S, Szamowskia R, et al. The origin of Raynaud’s phenomenon. J Cardiovasc Surg 1978; 19: 607–14Google Scholar
  26. 26.
    Gerbracht DD, Steen VD, Ziegler GL, et al. Evolution of primary Raynaud’s phenomenon (Raynaud’s disease) to connective tissue disease. Arthritis Rheum 1985; 28: 87–92PubMedCrossRefGoogle Scholar
  27. 27.
    Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. Arch Intern Med 1996; 156: 1421–5PubMedCrossRefGoogle Scholar
  28. 28.
    Maricq HF, Valter I, Maricq JG. An objective method to estimate the severity of Raynaud phenomenon: digital blood pressure response to cooling. Vasc Med 1998; 3(2): 109–13PubMedGoogle Scholar
  29. 29.
    Planchon B, De Faucal P, Essboui S, et al. A quantitative test for measuring reactivity to cold by the digital plethsmography technique: application to 66 control subjects and 65 patients with Raynaud’s phenomenon. Angiology 1986; 37(6): 433–9PubMedCrossRefGoogle Scholar
  30. 30.
    Friedman RR. Physiologic mechanisms of temperature biofeedback. Biofeedback Self Regul 1991; 16: 95–115CrossRefGoogle Scholar
  31. 31.
    Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud’s syndrome with traditional Chinese acupuncture. J Intern Med 1997; 241: 119–24PubMedCrossRefGoogle Scholar
  32. 32.
    Schwartz JB. Clinical pharmacology. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principles of geriatric medicine and gerontology. 3rd ed. New York: McGraw-Hill Inc., 1994: 259–76Google Scholar
  33. 33.
    Tinetti ME, Doucette J, Claus E. The contributions of predisposing and situational risk factors to serious fall injuries. J Am Geriatr Soc 1995; 43: 1207–13PubMedGoogle Scholar
  34. 34.
    Rodeeheffer RJ, Rommer JA, Wigley F, et al. Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon. N Engl J Med 1983; 308: 880–3CrossRefGoogle Scholar
  35. 35.
    Winston EL, Pariser KM, Miller KB, et al. Nifedipine as a therapeutic modality for Raynaud’s phenomenon. Arthritis Rheum 1983; 26: 1177–80PubMedCrossRefGoogle Scholar
  36. 36.
    Malamet R, Wise RA, Ettinger WH, et al. Nifedipine on the treatment of Raynaud’s phenomenon: evidence for inhibition of platelet activity. Am J Med 1985; 78: 602–8PubMedCrossRefGoogle Scholar
  37. 37.
    Gjorup T, Kelback H, Hartling OJ, et al. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud’s phenomenon. Am Heart J 1986; 111: 742–45PubMedCrossRefGoogle Scholar
  38. 38.
    Rhedda A, McCans J, Willan AR, et al. A double-blind placebo controlled crossover randomized trial of diltiazem in Raynaud’s phenomenon. J Rheumatol 1985; 12: 724–7PubMedGoogle Scholar
  39. 39.
    Wigley FM, Wise RA, Malamet R, et al. Nicardipine in the treatment of Raynaud’s phenomena: dissociation of platelet activation from vasospasm. Arthritis Rheum 1987; 30: 281–6PubMedCrossRefGoogle Scholar
  40. 40.
    Challenor VF, Waller DG, Francis DA, et al. Nisoldipine in primary Raynaud’s phenomenon. Eur J Clin Pharmacol 1987; 33: 27–30PubMedCrossRefGoogle Scholar
  41. 41.
    Sturgill MG. Seibold JR. Rational use of calcium-channel antagonists in Raynaud’s phenomenon. Curr Opin Rheumatol 1998; 10(6): 584–8PubMedCrossRefGoogle Scholar
  42. 42.
    Silvestry FE, Kimmel SE. Calcium-channel blockers in ischemic heart disease. Curr Opin Cardiol 1996; 11: 434–9PubMedCrossRefGoogle Scholar
  43. 43.
    Pstay BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739–45CrossRefGoogle Scholar
  44. 44.
    Furberg CD, Psaty BM, Myer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–31PubMedCrossRefGoogle Scholar
  45. 45.
    Pahor M, Guralnik JM, Corti MC, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191–7PubMedGoogle Scholar
  46. 46.
    Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335(15): 1107–14PubMedCrossRefGoogle Scholar
  47. 47.
    Janini SD, Scott DGI, Coppock JS, et al. Enalapril in Raynaud’s phenomenon. J Clin Pharm Ther 1988; 13: 145–50PubMedCrossRefGoogle Scholar
  48. 48.
    Pancera P, Sansone S, Secchi S, et al. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud’s phenomenon. J Intern Med 1997; 242(5): 373–6PubMedCrossRefGoogle Scholar
  49. 49.
    Neilson SL, Vitting K, Rasmussen K. Prazosin treatment of primary Raynaud’s phenomenon. Eur J Clin Pharmacol 1983; 24: 421–3CrossRefGoogle Scholar
  50. 50.
    Russell IJ, Lessard JA. Prazosin treatment of Raynaud’s phenomenon: a double-blind single crossover study. J Rheumatol 1985; 12: 94–8PubMedGoogle Scholar
  51. 51.
    Wollersheim H, Thien T, Fennis J, et al. Double-blind, placebo-controlled study of prazosin in Raynaud’s phenomenon. Clin Pharmacol Ther 1986; 40: 219–25PubMedCrossRefGoogle Scholar
  52. 52.
    Franks AG. Topical glyceryl trinitrate as adjunctive treatment in Raynaud’s disease. Lancet 1982; I: 76–7CrossRefGoogle Scholar
  53. 53.
    Whitmore SE, Wigley FM, Wise RA. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud’s phenomenon. J Rheumatol 1995; 22: 50–4PubMedGoogle Scholar
  54. 54.
    Jaffee IA. Serotonin reuptake inhibitors in Raynaud’s phenomena [letter]. Lancet 1995; 345: 1378CrossRefGoogle Scholar
  55. 55.
    Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120: 199–206PubMedGoogle Scholar
  56. 56.
    Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 1407–14Google Scholar
  57. 57.
    Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud’s secondary to systemic sclerosis: a multi-center, placebo-controlled double-blind study. Arthritis Rheum 1998; 41: 670–7PubMedCrossRefGoogle Scholar
  58. 58.
    Tsukamoto H, Nagasawa K. Successful treatment of Raynaud’s phenomenon with limaprost, an oral prostaglandin E1 analogue [letter]. Br J Rheumatol 1991; 30: 317PubMedCrossRefGoogle Scholar
  59. 59.
    Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized study. BMJ 1989; 298: 561–3PubMedCrossRefGoogle Scholar
  60. 60.
    Cattral MS, Altraif I, Greig P, et al. Toxic effects of intravenous and oral prostaglandin therapy in patients with liver disease. Am J Med 1994; 97: 369–73PubMedCrossRefGoogle Scholar
  61. 61.
    Bunker CB, Reavley C, O’Shaughnessy DJ, et al. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet 1993; 342: 80–3PubMedCrossRefGoogle Scholar
  62. 62.
    Bunker CB, Terenghi G, Springall DR, et al. Deficiency of calcitonin gene-related peptide in Raynaud’s phenomenon. Lancet 1990; 336: 1530–3PubMedCrossRefGoogle Scholar
  63. 63.
    Khan F, Litchfield SJ, McLaren M, et al. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud’s phenomenon. Arthritis Rheum 1997; 40: 352–7PubMedCrossRefGoogle Scholar
  64. 64.
    Cimminiello C, Milani M, Uberti T, et al. Endothelin, vasoconstriction, and endothelial damage in Raynaud’s phenomenon. Lancet 1991; 337: 114–5PubMedCrossRefGoogle Scholar
  65. 65.
    Fritzler MJ, Hart DA. Prolonged improvement of Raynaud’s phenomenon and scleroderma after recombinant tissue plasminogen activator therapy. Arthritis Rheum 1990; 33: 274–6PubMedCrossRefGoogle Scholar
  66. 66.
    Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med 1998; 129: 597–604PubMedGoogle Scholar
  67. 67.
    Simoons ML. Risk-benefit of thrombolysis. Cardiol Clin 1995; 13: 339–45PubMedGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Shari M. Ling
    • 1
  • Fredrick M. Wigley
    • 2
  1. 1.Division of Geriatric Medicine and Gerontology and Division of RheumatologyThe Johns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Division of RheumatologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations